Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 17, 2020International Journal of Molecular SciencesOpen Access

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future

View Full Paper
Ask AI
Bookmark
Share

Authors

IUIris Z. UrasComprehensive Cancer Center ViennaHMHerwig P. MollComprehensive Cancer Center ViennaECEmilio CasanovaComprehensive Cancer Center Vienna

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Uras et al. (2020) studied this question.

synapsesocial.com/papers/6a6aba6d26cff2e2f6f42860https://doi.org/10.3390/ijms21124325
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice2010 · 113 citations
  2. 2A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours2019 · 106 citations
  3. 3Direct Demonstration of Geranylgeranylation and Farnesylation of Ki-Ras in Vivo1997 · 371 citations
  4. 4KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition2018 · 272 citations
  5. 5Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy2015 · 232 citations